We are live on ! Find out more
INBX

Inhibrx, Inc. Common Stock

Delisted

INBX was delisted on the 29th of May, 2024.

126 hedge funds and large institutions have $1.34B invested in Inhibrx, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 38 increasing their positions, 39 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

1% less funds holding

Funds holding: 127126 (-1)

3% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 39

4% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 27

14% less capital invested

Capital invested by funds: $1.55B → $1.34B (-$215M)

44% less call options, than puts

Call options by funds: $2.44M | Put options by funds: $4.33M

Holders
126
Holders Change
-1
Holders Change %
-0.79%
% of All Funds
1.81%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
26
Increased
38
Reduced
39
Closed
27
Calls
$2.44M
Puts
$4.33M
Net Calls
-$1.88M
Net Calls Change
-$47.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$9.86M +$2.6M +71,200 +34%
SCM
27
Soleus Capital Management
Connecticut
$9.36M +$9.22M +252,871 +1,686%
WCMNY
28
Westchester Capital Management (New York)
New York
$9M +$9.39M +257,368 New
Charles Schwab
29
Charles Schwab
California
$8.09M +$57.2K +1,568 +0.7%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$7.06M +$3.6M +98,702 +96%
Russell Investments Group
31
Russell Investments Group
United Kingdom
$6.66M -$8.94M -245,061 -56%
PIM
32
Platinum Investment Management
Australia
$5.1M -$795K -21,797 -13%
CF
33
Cantor Fitzgerald
New York
$4.88M +$5.1M +139,715 New
HighTower Advisors
34
HighTower Advisors
Illinois
$4.61M
LNWWM
35
Laird Norton Wetherby Wealth Management
California
$4.58M -$193K -5,305 -4%
Wellington Management Group
36
Wellington Management Group
Massachusetts
$4.55M -$560K -15,354 -11%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$3.79M -$235K -6,456 -6%
MWA
38
Meridian Wealth Advisors
Texas
$3.5M -$814K -22,315 -18%
AA
39
AQR Arbitrage
Connecticut
$3.42M +$3.57M +97,774 New
N
40
Nuveen
North Carolina
$2.9M -$43.1K -1,182 -1%
Two Sigma Investments
41
Two Sigma Investments
New York
$2.74M +$2.57M +70,500 +892%
JP Morgan Chase
42
JP Morgan Chase
New York
$2.54M +$775K +21,238 +41%
CM
43
Caption Management
Oklahoma
$2.28M -$1.08M -29,713 -31%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$2.23M -$1.55M -42,485 -40%
Ensign Peak Advisors
45
Ensign Peak Advisors
Utah
$1.96M
Deutsche Bank
46
Deutsche Bank
Germany
$1.92M +$1.4M +38,496 +236%
YCM
47
Yakira Capital Management
Connecticut
$1.88M +$1.96M +53,762 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.8M +$85.3K +2,338 +5%
BC
49
Birchview Capital
Vermont
$1.69M
PHS
50
PFM Health Sciences
California
$1.68M -$17.9M -490,046 -91%

INBX Hedge Fund Activity: Q1 2024 in Review

126 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q1 2024, worth a combined $1.34B — down 14% from $1.55B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of INBX and 26 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 38 added.

The largest buyer was Alpine Associates Management, opening a new position worth an estimated $38.5M. The largest seller was Woodline Partners, exiting entirely with an estimated $88.1M sold.

  • 126 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q1 2024, down from 127 in Q4 2023.
  • Funds reported $1.34B of Inhibrx, Inc. Common Stock stock for Q1 2024, down 14% quarter-over-quarter.
  • 26 funds opened new Inhibrx, Inc. Common Stock positions in Q1 2024 and 27 closed out, a net change of -1 holder.
  • The largest Inhibrx, Inc. Common Stock buyer in Q1 2024 was Alpine Associates Management, an estimated $38.5M added.
  • The largest Inhibrx, Inc. Common Stock seller in Q1 2024 was Woodline Partners, an estimated $88.1M sold.

Based on aggregated 13F filings for Q1 2024.